InMed Announces Results of 2023 Annual General Meeting

Rhea-AI Summary

InMed Pharmaceuticals Inc. (NASDAQ: INM) confirms approval of all matters at the annual general meeting of shareholders, including the election of all director nominees. A total of 1,292,647 common shares, representing approximately 38.84% of the Company's issued and outstanding common shares, were represented at the Meeting.

Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 27, 2023, were approved by the shareholders. A total of 1,292,647 common shares of the Company, representing approximately 38.84% of the Company's 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the Meeting. In particular, shareholders approved the election of all director nominees to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Results of the vote for the election of directors at the Meeting are set out as follows:

Director	Votes For			Withheld Votes
	Number	Percentage		Number	Percentage
Eric A. Adams	160,711	76.09%		50,513	23.91%
Janet Grove	141,882	67.17%		69,342	32.83%
Andrew Hull	141,398	66.94%		69,826	33.06%
Nicole Lemerond	145,865	69.06%		65,359	30.94%
Bryan Baldasare	145,659	68.96%		65,565	31.04%

 

InMed filed a report of voting results on SEDAR at www.sedarplus.ca on December 19, 2023.

About InMed:

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.

Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: cclancy@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/191678

FAQ

What is the company name and ticker symbol of the pharmaceutical company involved in the annual general meeting of shareholders?

The company involved in the annual general meeting of shareholders is InMed Pharmaceuticals Inc. and its ticker symbol is INM.

What was confirmed at the annual general meeting of shareholders for InMed Pharmaceuticals Inc.?

At the Meeting, InMed Pharmaceuticals Inc. confirmed the approval of all matters, including the election of all director nominees.

Where can the report of voting results be found for InMed Pharmaceuticals Inc.?

The report of voting results for InMed Pharmaceuticals Inc. can be found on SEDAR at www.sedarplus.ca.